Holzgreve, Adrien http://orcid.org/0000-0002-9566-8438
Taugner, Julian
Käsmann, Lukas
Müller, Philipp
Tufman, Amanda
Reinmuth, Niels
Li, Minglun
Winkelmann, Michael
Unterrainer, Lena M.
Nieto, Alexander E.
Bartenstein, Peter
Kunz, Wolfgang G.
Ricke, Jens
Belka, Claus
Eze, Chukwuka
Unterrainer, Marcus
Manapov, Farkhad
Funding for this research was provided by:
LMU Munich Clinician Scientist Program (MCSP Track Metiphys, MCSP Track Metiphys)
Universitätsklinik München
Article History
Received: 3 January 2023
Accepted: 5 March 2023
First Online: 23 March 2023
Declarations
:
: The institutional review board of the Ludwig-Maximilians-Universität (LMU) approved the retrospective data analysis (#17–230). The study was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the declaration of Helsinki.
: All patients included in the study gave written consent for the PET/CT scans as part of the clinical routine.
: Farkhad Manapov receives an unrestricted Research Institutional Grant from AstraZeneca. Farkhad Manapov receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. Farkhad Manapov serves in the advisory board of AstraZeneca, Novartis. The remaining authors did not declare conflicts of interest related to this work.